Greg P. Licholai MD, MBA

Greg is President and Chief Scientific Officer at Castle Creek Pharmaceuticals. He is a member of the Executive Leadership Team and is responsible for all research and development activities, technical operations, medical affairs and the company’s scientific, regulatory, medical and clinical strategies. Greg is on faculty at the Yale School of Management, teaches the capstone lectures on Sustainable Innovation in Healthcare, and has written multiple articles on biopharmaceutical innovation. Previously he was founder and President of Elpidera Therapeutics, a Moderna Therapeutics venture portfolio company focused on developing messenger RNA therapies for rare genetic and metabolic diseases. He was a partner-level consultant at McKinsey & Company, and Senior Vice President for Real World and Late Stage Research at Quintiles, Inc. He was Chief Operating Officer at Proteostasis, focused on rare disease. He was one of the original employees at Amicus Therapeutics, focused on pharmacological chaperones for rare diseases. He was also co-founder of Immunome, a biotechnology firm with a proprietary antibody platform for oncology. He was a venture capitalist at Domain Associates. He was director of Ventures and Business Development at Medtronic Neurological. Greg attended Columbia University and Boston College, received an M.D. from Yale Medical School and M.B.A from Harvard Business School. He trained at the Brigham and Women’s, Children’s, and Massachusetts General Hospitals. He was a Howard Hughes Medical Institute Research Scholar at the National Institutes of Health. He performed research in molecular genetics at Yale University. He worked in molecular oncology at Rockefeller University. He is on the advisory board of the National Tay Sachs and Allied Disease Foundation, the Partnership for Palliative Care, and Yale Health Conference.